18F‐Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment within a Randomized Controlled Trial in Giant Cell Arteritis | Synapse
April 8, 2026
18F‐Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment within a Randomized Controlled Trial in Giant Cell Arteritis
Puntos clave
Assess the relationship between vascular FDG-PET activity and clinical assessments in giant cell arteritis.
Conducted a randomized controlled trial
Utilized FDG-PET imaging for vascular assessment
Evaluated discordance between imaging and clinical findings
Identified instances where FDG-PET activity did not match clinical assessments
Indicated a need for further exploration of imaging outcomes in trials
Resumen
Vascular FDG-PET activity may be discordant with clinical assessment, particularly in subsets of patients with GCA. Imaging-based outcome measures should remain exploratory in future therapeutic trials.